SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome‐Mediated Autocrine Manner

Abstract

Endothelial dysfunction is considered a predominant driver for pulmonary vascular remodeling in pulmonary hypertension (PH). SOX17, a key regulator of vascular homoeostasis, has been found to harbor mutations in PH patients, which are associated with PH susceptibility. Here, this study explores whether SOX17 mediates the autocrine activity of pulmonary artery ECs to maintain endothelial function and vascular homeostasis in PH and its underlying mechanism. It is found that SOX17 expression is downregulated in the endothelium of remodeled pulmonary arteries in IPH patients and SU5416/hypoxia (Su/hypo)‐induced PH mice as well as dysfunctional HPAECs. Endothelial knockdown of SOX17 accelerates the progression of Su/hypo‐induced PH in mice. SOX17 overexpression in the pulmonary endothelium of mice attenuates Su/hypo‐induced PH. SOX17‐associated exosomes block the proliferation, apoptosis, and inflammation of HPAECs, preventing pulmonary arterial remodeling and Su/hypo‐induced PH. Mechanistic analyses demonstrates that overexpressing SOX17 promotes the exosome‐mediated release of miR‐224‐5p and miR‐361‐3p, which are internalized by injured HPAECs in an autocrine manner, ultimately repressing the upregulation of NR4A3 and PCSK9 genes and improving endothelial function. These results suggest that SOX17 is a key gene in maintaining endothelial function and vascular homeostasis in PH through regulating exosomal miRNAs in an autocrine manner.

Abstract

Endothelial dysfunction is considered a predominant driver for pulmonary vascular remodeling in pulmonary hypertension. In this study, it is shown that SOX17, serving as a key factor in maintaining endothelial function and vascular homeostasis, prevents endothelial dysfunction and pulmonary arterial remodeling through regulating exosomal miRNAs in an autocrine manner in pulmonary hypertension.